XML 36 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
 3 Months Ended 9 Months Ended
Aug. 29, 2017
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Segment
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Significant Accounting Policies [Line Items]            
Restricted cash balances as collateral for corporate credit cards   $ 80,000   $ 80,000   $ 80,000
Marketable securities, weighted average remaining maturity       8 months    
Research and development expense   8,956,468 $ 5,852,121 $ 23,714,932 $ 13,941,283  
Deferred revenue   41,175,600   41,175,600    
Impairment of Long-Lived Assets       0 0  
Impairment of goodwill       0 0  
Revenues from product sales to date       $ 0    
Number of operating segments | Segment       1    
In-Process Research and Development            
Significant Accounting Policies [Line Items]            
Asset impairment charges   0 0 $ 0 0  
Janssen and JJDC | Co-Development and License Agreement            
Significant Accounting Policies [Line Items]            
Research and development expense   4,500,000 $ 3,500,000 11,200,000 $ 3,500,000  
Janssen | Amendment to Co-Development and License Agreement | Seltorexant            
Significant Accounting Policies [Line Items]            
Upfront payment $ 30,000,000          
Accrued collaborative expenses 11,200,000          
Deferred revenue   41,200,000   41,200,000    
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Upfront Payment            
Significant Accounting Policies [Line Items]            
Deferred revenue   30,000,000   30,000,000    
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Previously Accrued Collaborative Expenses            
Significant Accounting Policies [Line Items]            
Deferred revenue   11,200,000   11,200,000    
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Phase 3 Insomnia Trail            
Significant Accounting Policies [Line Items]            
Payment start of Phase 20,000,000          
Payment upon enrollment of patients $ 20,000,000          
Percentage of patients to be enrolled 50.00%          
Accrued collaborative expenses $ 11,200,000          
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Phase 3 Insomnia Trail | Upfront Payment            
Significant Accounting Policies [Line Items]            
Deferred revenue   30,000,000   30,000,000    
Janssen | Amendment to Co-Development and License Agreement | Seltorexant | Phase 3 Insomnia Trail | Previously Accrued Collaborative Expenses            
Significant Accounting Policies [Line Items]            
Deferred revenue   $ 11,200,000   $ 11,200,000